Advancing the Science

Mayo Clinic Medical Science Blog

nicoleferrara

Nicole Brudos Ferrara @nicoleferrara

Activity by Nicole Brudos Ferrara @nicoleferrara

nicoleferrara

Tue, Feb 28 at 8:00am CDT by @nicoleferrara · View  

More women eligible for Herceptin, benefit uncertain

Updated guidelines underscore need to identify the most optimal candidates for HER2-directed therapy.

Changes to HER2 testing guidelines for breast cancer in 2013 significantly increased the number of patients who test positive for HER2 breast cancer, Mayo Clinic researchers have found.

The researchers published their HER2 breast cancer study results online July 25, 2016, in the Journal of Clinical Oncology.

Cancers that have an excess of HER2 protein or extra copies of the HER2 gene are called HER2 positive and can be treated with drugs such as Herceptin that target the HER2 protein. HER2-positive cancers tend to be more aggressive and spread more quickly than do other breast cancers.
[...]

Click here to view the rest of the post

Login here to comment.
nicoleferrara

Thu, Feb 16 at 8:00am CDT by @nicoleferrara · View  

Drug combo safe for diffuse large B-cell lymphoma

 

Drugs targeting the P13K-mTOR pathway add benefit when combined with standard R-CHOP therapy.

 

The drug everolimus can be safely combined with R-CHOP for new, untreated diffuse large B-cell lymphoma, according to the results of a pilot study by Mayo Clinic researchers.

The researchers published their study findings in the July 2016 issue of The Lancet Haematology.

R-CHOP is a combination of drugs used to treat lymphoma that includes rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone.

Photograph of Patrick B. Johnston, M.D., Ph.D. Patrick B. Johnston, M.D., [...]

Click here to view the rest of the post

Login here to comment.
nicoleferrara

Sun, Feb 5 at 8:00am CDT by @nicoleferrara · View  

Researchers identify unique breast microbiome

A team of Mayo Clinic researchers has identified evidence of bacteria in breast tissue and found differences between women with and without breast cancer.

These research findings were published in the August 3, 2016, issue of Scientific Reports.

Photograph of Tina J. Hieken, M.D.

Tina J. Hieken, M.D.

"Our research found that breast tissue samples obtained in the operating room under sterile conditions contain bacterial DNA, even when there is no sign of infection," said Tina J. Hieken, M.D., a breast surgical oncologist at Mayo Clinic in Rochester, Minnesota. "Furthermore, we identified significant differences in the breast tissue microbiome of women with cancer versus women without cancer and the [...]

Click here to view the rest of the post

Login here to comment.
nicoleferrara

Dec 29, 2016 by @nicoleferrara · View  

Drug combo stems tumor growth in lung cancer

Researchers on Mayo Clinic's campus in Jacksonville, Florida, have shut down one of the most common and lethal forms of lung cancer by combining the rheumatoid arthritis drug auranofin with an experimental targeted agent.

The combination therapy worked in a laboratory study to stop lung adenocarcinoma associated with mutation of the KRAS gene. The study was published in the March 14, 2016, issue of Cancer Cell.

Alan Fields, Ph.D.

Alan Fields, Ph.D.

"If our approach works in KRAS-mediated lung adenocarcinoma, it may work in other KRAS-mediated cancers, such as pancreatic cancer and colon cancer, as well as other cancer types," said [...]

Click here to view the rest of the post

Login here to comment.
nicoleferrara

Dec 15, 2016 by @nicoleferrara · View  

Combination therapy improves survival in adults with glioma

Radiation plus three-drug combo boosts progression-free survival and overall survival.

Patients with a low-grade type of brain tumor called glioma who received radiation therapy plus a chemotherapy regimen, including procarbazine, lomustine and vincristine (PCV), experienced a longer progression-free survival and overall survival than did patients who received radiation therapy alone.

These are the results of a clinical trial called Radiation Therapy Oncology Group (RTOG) 9802 that were published in the April 7, 2016, issue of the New England Journal of Medicine.

Jan Buckner, M.D.

"This is the first phase III trial to demonstrate conclusively a [...]

Click here to view the rest of the post

Login here to comment.
nicoleferrara

Oct 23, 2014 by @nicoleferrara · View  

We Can Do More! Be an Advocate for Cancer Research Funding

The post below was written by Toni Kay Mangskau, clinical trials referral coordinator at Mayo Clinic Cancer Center and an active volunteer for the American Cancer Society and the National Patient Advocate Foundation.

Three generations of womenSeptember 2014 was the 10th anniversary of the death of my brother-in-law, Bruce, from cancer. I carry close to my heart a family conversation about Bruce urgently looking for any clinical trial opportunities in the world so he could possibly have more time to live. Unfortunately, his health declined and he was hospitalized in intensive care. As I walked into his hospital room, Bruce was surrounded by his wife, mother and children. Except for the medical machines, there was a [...]

Click here to view the rest of the post

Login here to comment.
nicoleferrara

Apr 3, 2014 by @nicoleferrara · View  

Volunteers Sought: People with HPV-positive Tonsil and Tongue Cancers

http://youtu.be/3UetqTM9P5I

Mayo Clinic in Rochester, Minn., is seeking volunteers for a clinical trial for patients with human papillomavirus (HPV) positive tonsil or tongue (oropharynx) cancer whose disease has not spread outside of the neck. The purpose of the study is to find out if reducing treatment time and dosage can control the cancer while decreasing short-term and long-term side effects associated with treatment.

Who is eligible?
You may be eligible to participate in this study if you:

  • Have been diagnosed with HPV-positive tonsil or tongue (oropharynx) cancer.
  • Are 18 years of age or older.
  • Have never, or have almost never, smoked. (For medical professionals: Less than a 10 pack-year smoking history or less than a [...]

Click here to view the rest of the post

Login here to comment.
Loading information...
Contact Us · Privacy Policy